{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Yao N"],"funding":["National Natural Science Foundation of China"],"pagination":["1197-1206"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9812094"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["101(11)"],"pubmed_abstract":["<h4>Introduction</h4>Mother-to-child transmission (MTCT) of the hepatitis B virus (HBV) is a serious public health challenge. Estimating HBV MTCT incidence by region under different prophylaxis regimens is critical to understanding the regional disease burden and prioritizing interventions. This study aimed to calculate HBV MTCT incidence under different prophylaxis regimens globally and regionally and identify the HBV DNA threshold for maternal peripartum antiviral prophylaxis.<h4>Material and methods</h4>This review was registered in advance in PROSPERO (CRD 42019120567). We searched PubMed, Embase, China National Knowledge Infrastructure, ClinicalTrials.gov, and Cochrane Library databases for studies on MTCT in pregnant women with chronic HBV infection from their inception until June 13"],"journal":["Acta obstetricia et gynecologica Scandinavica"],"pubmed_title":["Incidence of mother-to-child transmission of hepatitis B in relation to maternal peripartum antiviral prophylaxis: A systematic review and meta-analysis."],"pmcid":["PMC9812094"],"funding_grant_id":["81770594","81670537"],"pubmed_authors":["Liu J","Fu S","Li J","Yao N","Ji F","Feng Y","Zhao Y","Tian Z","Yang Y","Chen Y","Luo X","Wu Y","Chen T"],"additional_accession":[]},"is_claimable":false,"name":"Incidence of mother-to-child transmission of hepatitis B in relation to maternal peripartum antiviral prophylaxis: A systematic review and meta-analysis.","description":"<h4>Introduction</h4>Mother-to-child transmission (MTCT) of the hepatitis B virus (HBV) is a serious public health challenge. Estimating HBV MTCT incidence by region under different prophylaxis regimens is critical to understanding the regional disease burden and prioritizing interventions. This study aimed to calculate HBV MTCT incidence under different prophylaxis regimens globally and regionally and identify the HBV DNA threshold for maternal peripartum antiviral prophylaxis.<h4>Material and methods</h4>This review was registered in advance in PROSPERO (CRD 42019120567). We searched PubMed, Embase, China National Knowledge Infrastructure, ClinicalTrials.gov, and Cochrane Library databases for studies on MTCT in pregnant women with chronic HBV infection from their inception until June 13","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2026-03-17T16:02:33.936Z","creation":"2025-04-04T21:04:31.427Z"},"accession":"S-EPMC9812094","cross_references":{"pubmed":["36082797"],"doi":["10.1111/aogs.14448"]}}